For Referring Physicians
Information on Pluvicto and Lutathera Outcomes and Safety
Pluvicto® (Lutetium Lu 177 vipivotide tetraxetan)
Pluvicto is a radioligand therapy approved for metastatic castration-resistant prostate cancer (mCRPC) that expresses prostate-specific membrane antigen (PSMA). It targets PSMA-expressing cells to deliver targeted radiation therapy.
- Clinical Outcomes:
- The VISION trial demonstrated a significant improvement in both progression-free survival (PFS) and overall survival (OS) in patients receiving Pluvicto in addition to standard of care.
- Notable reduction in PSA levels and radiographic tumor burden was observed in a large proportion of patients.
- Median OS in treated patients was approximately 15.3 months compared to 11.3 months in controls.
- Safety Profile:
- Most common side effects include fatigue, dry mouth, nausea, and bone marrow suppression (anemia, thrombocytopenia).
- Radiation safety protocols are strictly adhered to; patients receive detailed radiation safety instructions before and after therapy.
- Side effects are generally mild to moderate and manageable with supportive care.
Lutathera® (Lutetium Lu 177 dotatate)
Lutathera is approved for the treatment of somatostatin receptor-positive gastroenteropancreatic neuroendocrine tumors (GEP-NETs).
- Clinical Outcomes:
- The NETTER-1 trial showed significant improvement in progression-free survival, with a 79% risk reduction of disease progression compared to high-dose octreotide alone.
- Objective response rates exceeded 18%, with some patients achieving durable partial or complete responses.
- Safety Profile:
- Common side effects include nausea, vomiting, and mild bone marrow suppression.
- Long-term risks (e.g., renal or hematologic toxicity) are monitored with regular blood tests and renal assessments.
- Lutathera has a favorable safety record with strict quality control and patient monitoring.
Contact Information & Locations
Crescent Theranostics proudly serves patients from across the region with two convenient outpatient locations in Anaheim and Temecula, California. Our team is here to guide you through every step—from scheduling your first consultation to understanding insurance and preparing for treatment.
Anaheim Office
2050 South Euclid Street, Anaheim, CA 92802
Temecula Office
27262 Via Industria, Temecula, CA 92590
To schedule an appointment, learn more about Pluvicto, Lutathera, or our upcoming treatment options, contact us by phone or visit our website. We’re here to answer your questions and help you take the next step toward personalized, life-changing cancer care.
For more information, you can visit their website directly or contact Crescent Theranostics for appointment scheduling and inquiries about available treatments.